Inovio Pharmaceuticals, Inc.

NasdaqCM:INO Stock Report

Market Cap: US$47.8m

Inovio Pharmaceuticals Management

Management criteria checks 3/4

Inovio Pharmaceuticals' CEO is Jacqueline Shea, appointed in May 2022, has a tenure of 2.67 years. total yearly compensation is $2.44M, comprised of 30.8% salary and 69.2% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $61.58K. The average tenure of the management team and the board of directors is 3.6 years and 6 years respectively.

Key information

Jacqueline Shea

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage30.8%
CEO tenure2.7yrs
CEO ownership0.1%
Management average tenure3.6yrs
Board average tenure6yrs

Recent management updates

Recent updates

Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

Aug 11
Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

May 15
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

May 13
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Oct 23
Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Oct 13

Inovio Pharmaceuticals: Long On Promise, Short On Results

Sep 27

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Aug 09

Inovio: After All These Years

Jul 19

Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022

Apr 15

Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Mar 21
Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Inovio Undervalued On Potential 2022 Catalyst

Jan 26

Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Dec 31
Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

CEO Compensation Analysis

How has Jacqueline Shea's remuneration changed compared to Inovio Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$113m

Jun 30 2024n/an/a

-US$122m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$751k

-US$135m

Sep 30 2023n/an/a

-US$165m

Jun 30 2023n/an/a

-US$168m

Mar 31 2023n/an/a

-US$241m

Dec 31 2022US$4mUS$730k

-US$280m

Sep 30 2022n/an/a

-US$332m

Jun 30 2022n/an/a

-US$355m

Mar 31 2022n/an/a

-US$328m

Dec 31 2021US$2mUS$468k

-US$304m

Sep 30 2021n/an/a

-US$221m

Jun 30 2021n/an/a

-US$142m

Mar 31 2021n/an/a

-US$188m

Dec 31 2020US$2mUS$431k

-US$166m

Sep 30 2020n/an/a

-US$180m

Jun 30 2020n/an/a

-US$222m

Mar 31 2020n/an/a

-US$123m

Dec 31 2019US$1mUS$335k

-US$119m

Compensation vs Market: Jacqueline's total compensation ($USD2.44M) is above average for companies of similar size in the US market ($USD649.25K).

Compensation vs Earnings: Jacqueline's compensation has been consistent with company performance over the past year.

CEO

Jacqueline Shea (58 yo)

2.7yrs

Tenure

US$2,438,908

Compensation

Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...

Leadership Team

NamePositionTenureCompensationOwnership
Jacqueline Shea
CEO, President & Director2.7yrsUS$2.44m0.13%
$ 61.6k
Peter Kies
Chief Financial Officer22.6yrsUS$1.16m0.095%
$ 45.3k
Laurent Humeau
Chief Scientific Officer & Chairman of the Scientific Advisory Board5.8yrsUS$1.14m0.093%
$ 44.5k
Thomas Hong
Manager of Investor Relationsno datano datano data
Robert Crotty
General Counsel & Chief Compliance Officer3.2yrsno datano data
E. Brandreth
Senior Vice President of Quality Assuranceno datano datano data
Jeffrey Skolnik
Senior Vice President of Clinical Development4.3yrsno datano data
Robert Juba
Senior Vice President of Biological Manufacturing & Clinical Supply Management4.3yrsno datano data
Shawn Bridy
Senior Vice President of Business Development4yrsno datano data
David Liebowitz
Senior Vice President of Early-Stage Clinical Developmentless than a yearno datano data
Michael Sumner
Chief Medical Officer2.6yrsno data0.031%
$ 15.0k
Cheryl Elder
Senior Vice President of Regulatory Affairs1.8yrsno datano data

3.6yrs

Average Tenure

58yo

Average Age

Experienced Management: INO's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jacqueline Shea
CEO, President & Director2.7yrsUS$2.44m0.13%
$ 61.6k
Laurent Humeau
Chief Scientific Officer & Chairman of the Scientific Advisory Boardless than a yearUS$1.14m0.093%
$ 44.5k
Wendy Yarno
Independent Director7.1yrsUS$123.69k0.032%
$ 15.3k
Lota Zoth
Independent Director6yrsUS$118.69k0.025%
$ 12.0k
Jay Shepard
Independent Director5yrsUS$119.31k0.027%
$ 12.9k
Simon Benito
Independent Chairman of Board of Directors21.1yrsUS$151.19k0.038%
$ 18.3k
David B. Weiner
Member of the Scientific Advisory Board & Director8.8yrsUS$201.79k0.32%
$ 151.0k
Stanley Plotkin
Member of Scientific Advisory Board15.6yrsno datano data
Ann Miller
Independent Director5.8yrsUS$126.94k0.030%
$ 14.1k
Roger Dansey
Independent Director3.7yrsUS$108.69k0.026%
$ 12.4k
Rafi Ahmed
Member of Scientific Advisory Board6.2yrsno datano data

6.0yrs

Average Tenure

67yo

Average Age

Experienced Board: INO's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 22:08
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Inovio Pharmaceuticals, Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Geoffrey MeachamBofA Global Research
Jonathan AschoffBrean Capital